Formulary guidance and transparency from P&T to point of care

Trends That Matter for Compounding Policies

Posted by Matt Breese on Jan 18, 2018

Find me on:


In our weekly Trends that Matter series, we provide infographics, articles and recent news from healthcare influencers to highlight general trends affecting the pharmaceutical industry. This week's featured topic is pharmacy compounding regulations.

The U.S. Food and Drug Administration recently issued it's 2018 Compounding Policy Priorities Plan. 

According to Scott Gottlieb, M.D. FDA Commissioner, one of the FDA's major goals with this plan is to ensure that medicines are meeting proper quality standards. 

"We will balance the need to preserve access to appropriately compounded drugs for patients who have a medical need for these products with the need to help protect patients from poor quality compounded drugs that could cause harm. At the same time, we’ll continue to take steps to preserve the new drug approval requirements that obligate sponsors to demonstrate that drugs are safe and effective for their intended purpose before they can be lawfully marketed."

Subscribe to the MMIT blog for more insights on trends affecting pharmaceutical manufacturers, providers and payers.

Subscribe for Weekly Trends that Matter 

Topics: Industry Trends